Welcome to our dedicated page for Accolade news (Ticker: ACCD), a resource for investors and traders seeking the latest updates and insights on Accolade stock.
This page provides a historical news archive for Accolade, Inc. (formerly Nasdaq: ACCD), a Personalized Healthcare company that combined virtual primary care and mental health, expert medical opinion, and care navigation for employers, health plans, and consumers. The news flow around Accolade documents its evolution as a public company and its eventual merger with Transcarent.
Readers can find company-issued announcements describing Accolade’s financial results, investor conference presentations, and guidance updates during its time as a listed company. These items include earnings releases, notices about upcoming quarterly results, and participation in healthcare and investor conferences, all framed around its Personalized Healthcare platform and focus on predictive engagement, proactive care, and addressing barriers to access and continuity of care.
The archive also includes press releases detailing strategic developments, such as the expansion of PlushCare, Accolade’s virtual health business unit, to accept Medicare Part B for direct-to-consumer virtual care. These releases describe efforts to broaden access to primary care, clinical weight management services, and mental health support for Medicare beneficiaries across all 50 states.
A significant portion of the news coverage centers on the acquisition of Accolade by Transcarent. Initial announcements describe a definitive agreement for Transcarent to acquire Accolade for cash consideration per share, followed by stockholder approval of the merger and, later, confirmation that the transaction was completed. These items explain that, after the merger, Accolade became part of a privately held company and its common stock would no longer be listed on Nasdaq or any public market.
Investors and researchers can use this news page to trace how Accolade positioned its Personalized Healthcare offerings, how it communicated with the market, and how the combination with Transcarent was described by both organizations over time.
Accolade, Inc. (NASDAQ: ACCD) reported a fiscal Q1 2021 revenue of $35.9 million, representing a 25% increase from $28.8 million in the same quarter last year. The growth was attributed to new customer acquisitions across various segments. The company introduced a pilot program with the Defense Health Agency, marking its entry into the federal government sector. Although the net loss decreased to $(14.0) million from $(15.9) million in Q1 2020, the adjusted gross margin fell to 38.3%. The company provided guidance for Q2 2021 and full-year fiscal 2021.
Accolade, Inc. (NASDAQ: ACCD) has successfully closed its initial public offering, offering 11,526,134 shares of common stock at a public price of $22.00 per share. This includes the full exercise of the underwriters' option to purchase an additional 1,503,408 shares. Major underwriters include Goldman Sachs, Morgan Stanley, and BofA Securities. The offering will aid Accolade in providing personalized healthcare solutions and enhancing its marketplace presence. This IPO allows the company to navigate the healthcare system and improve consumer engagement.